-
1دورية أكاديمية
المؤلفون: Amiot, A, Rahier, JF, Baert, F, Nahon, S, Hart, A, Viazis, N, Biancone, L, Domenech, E, Reenears, C, Peyrin-Biroulet, L, Beaugerie, L, Burisch, J
المصدر: Journal of Crohn's & colitis. 17(1):37-48
مصطلحات موضوعية: Medicin och hälsovetenskap
-
2دورية أكاديمية
المؤلفون: Wong, CRT, van Oostrom, J, Pittet, V, Bossuyt, P, Hanzel, J, Samaan, M, Tripathi, M, Czuber-Dochan, W, Burisch, J, Leone, S, Saldana, R, Baert, F, Kopylov, U, Jaghult, S, Adamina, M, Gecse, K, Arebi, N
المصدر: Journal of Crohn's & colitis. 18(6):875-884
مصطلحات موضوعية: Medicin och hälsovetenskap, Klinisk medicin, Gastroenterologi
-
3دورية أكاديمية
المؤلفون: Amiot, A, Rahier, JF, Baert, F, Nahon, S, Hart, A, Viazis, N, Biancone, L, Domenech, E, Reenears, C, Peyrin-Biroulet, L, Beaugerie, L, Burisch, J
المصدر: Journal of Crohn's & colitis. 17(6):1025-1025
مصطلحات موضوعية: Medicin och hälsovetenskap
-
4دورية أكاديمية
المؤلفون: Peyrin-Biroulet, L, Rahier, JF, Kirchgesner, J, Abitbol, V, Shaji, S, Armuzzi, A, Karmiris, K, Gisbert, JP, Bossuyt, P, Helwig, U, Burisch, J, Yanai, H, Doherty, GA, Magro, F, Molnar, T, Lowenberg, M, Halfvarson, J, Zagorowicz, E, Rousseau, H, Baumann, C, Baert, F, Beaugerie, L
المصدر: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 21(3):771
مصطلحات موضوعية: Medicin och hälsovetenskap
-
5دورية أكاديمية
المؤلفون: Hanzel, J, Bossuyt, P, Pittet, V, Samaan, M, Tripathi, M, Czuber-Dochan, W, Burisch, J, Leone, S, Saldana, R, Baert, F, Kopylov, U, Jaghult, S, Adamina, M, Arebi, N, Gecse, K
المصدر: Journal of Crohn's & colitis. 17(3):311-317
مصطلحات موضوعية: Medicin och hälsovetenskap
-
6دورية أكاديمية
المؤلفون: Laharie, David, D'haens, G., Nachury, Maria, Lambrecht, G., Bossuyt, P., Bouhnik, Yoram, Louis, E., Van Der Woude, C. J., Buisson, Anthony, Van Hootegem, P., Allez, Matthieu, Filippi, Jérôme, Brixi, Hedia, Gilletta, Cyrielle, Picon, Laurence, Baert, F., Vermeire, S., Duveau, Nicolas, Peyrin-Biroulet, Laurent
المساهمون: Université de Lille, Inserm, CHU Lille, Service d'Hépato-Gastro-Entérologie, Hôpital Haut-Lévêque CHU Bordeaux, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Service d'Hépatologie Gastro-entérologie CHU Clermont-Ferrand, CHU Clermont-Ferrand, Hopital Saint-Louis AP-HP AP-HP, Centre Hospitalier Universitaire de Nice CHU Nice, Hôpital l'Archet, Hôpital universitaire Robert Debré Reims, Service de Gastroentérologie et pancréatologie CHU Toulouse, Centre Hospitalier Régional Universitaire de Tours CHRU Tours, Centre Hospitalier de Roubaix, Centre Hospitalier Universitaire de Nancy CHU Nancy
مصطلحات موضوعية: Crohn's Disease, Deep Remission, Infliximab, Endoscopic Remission
الوصف: Background & Aims Crohn's disease (CD) patients included in the Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) trial started infliximab in combination with an immunosuppressant for 1 year. The aim of the present study was to determine the long-term disease course beyond the study period. Methods We compared the outcomes of patients who did or did not reach the primary end point of the TAILORIX trial, defined as sustained corticosteroid-free clinical remission from weeks 22 through 54, with no ulcers on ileocolonoscopy at week 54. The primary outcome of this follow-up study was the progression-free survival of CD defined by anal or major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. Results The 95 patients (median disease duration, 4.5 mo; interquartile range, 1.0–56.6 mo) analyzed, including 45 (47%) who achieved the primary end point, were followed up for a median duration of 64.2 months (interquartile range, 57.6–69.9 mo) after the end of the study period. There was no significant difference in CD progression-free survival at 1, 3, and 5 years between patients who achieved the TAILORIX primary end point and patients who did not (P = .64). No difference was observed between both groups for each component of CD progression: anal surgery, major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. Conclusions Achieving a sustained clinical remission off steroids with complete endoscopic remission in this cohort of 95 patients with early CD was not associated with less disease progression. Prospective trials to define the therapeutic goals that change the natural history of CD and prevent complications are needed.
وصف الملف: application/pdf
العلاقة: Clinical Gastroenterology and Hepatology; Clin Gastroenterol Hepatol; http://hdl.handle.net/20.500.12210/101015Test
-
7دورية أكاديمية
المؤلفون: Wong, C, van Oostrom, J, Bossuyt, P, Pittet, V, Hanzel, J, Samaan, M, Tripathi, M, Czuber-Dochan, W, Burisch, J, Leone, S, Saldana, R, Baert, F, Kopylov, U, Jaghult, S, Adamina, M, Gecse, K, Arebi, N
المصدر: Journal of Crohn's & colitis. 16(10):1511-1522
مصطلحات موضوعية: Medicin och hälsovetenskap
-
8دورية أكاديمية
المؤلفون: Louis, E, Resche-Rigon, M, Laharie, D, Satsangi, J, Ding, N, Siegmund, B, D'Haens, G, Picon, L, Bossuyt, P, Vuitton, L, Irving, P, Viennot, S, Lamb, CA, Pollok, R, Baert, F, Nachury, M, Fumery, M, Gilletta, C, Almer, S, Ben-Horin, S, Bouhnik, Y, Colombel, J-F, Hertervig, E, GETAID and the SPARE-Biocycle research group
الوصف: BACKGROUND: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our aim was to compare the relapse rate and the time spent in remission over 2 years between patients continuing combination therapy and those stopping infliximab or immunosuppressant therapy. METHODS: This multicentre, open-label, randomised controlled trial was performed in 64 hospitals in seven countries in Europe and Australia. Adult patients with Crohn's disease in steroid-free clinical remission for more than 6 months, on combination therapy of infliximab and immunosuppressant therapy for at least 8 months were randomly assigned (1:1:1) to either continue combination therapy (combination group), discontinue infliximab (infliximab withdrawal group), or discontinue immunosuppressant therapy (immunosuppressant withdrawal group). Randomisation was stratified according to disease duration before start of first anti-TNF treatment (≤2 or >2 years), failure of immunosuppressant therapy before start of infliximab, and presence of ulcers at baseline endoscopy. The patient number and group of each stratum were assigned by a central online randomisation website. Treatment was optimised or resumed in case of relapse in all groups. Participants, those assessing outcomes, and those analysing the data were not masked to group assignment. The coprimary endpoints were the relapse rate (superiority analysis) and time in remission over 2 years (non-inferiority analysis, non-inferiority margin 35 days). Analyses were done on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, NCT02177071, and with EU Clinical Trials Register, EUDRACT 2014-002311-41. The trial was completed in April, 2021. FINDINGS: Between Nov 2, 2015, and April 24, 2019, 254 patients were screened. Of these, 211 were randomised and 207 were ...
وصف الملف: application/pdf
العلاقة: https://openaccess.sgul.ac.uk/id/eprint/115531/1/1-s2.0-S2468125322003855-main.pdfTest; https://openaccess.sgul.ac.uk/id/eprint/115531/6/1-s2.0-S2468125322003855-mmc1.pdfTest; Louis, E; Resche-Rigon, M; Laharie, D; Satsangi, J; Ding, N; Siegmund, B; D'Haens, G; Picon, L; Bossuyt, P; Vuitton, L; et al. Louis, E; Resche-Rigon, M; Laharie, D; Satsangi, J; Ding, N; Siegmund, B; D'Haens, G; Picon, L; Bossuyt, P; Vuitton, L; Irving, P; Viennot, S; Lamb, CA; Pollok, R; Baert, F; Nachury, M; Fumery, M; Gilletta, C; Almer, S; Ben-Horin, S; Bouhnik, Y; Colombel, J-F; Hertervig, E; GETAID and the SPARE-Biocycle research group (2023) Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol, 8 (3). pp. 215-227. ISSN 2468-1253 https://doi.org/10.1016/S2468-1253Test(22)00385-5 SGUL Authors: Pollok, Richard Charles G
الإتاحة: https://doi.org/10.1016/S2468-1253Test(22)00385-5
https://openaccess.sgul.ac.uk/id/eprint/115531Test/
https://openaccess.sgul.ac.uk/id/eprint/115531/1/1-s2.0-S2468125322003855-main.pdfTest
https://openaccess.sgul.ac.uk/id/eprint/115531/6/1-s2.0-S2468125322003855-mmc1.pdfTest -
9دورية أكاديمية
المؤلفون: Caprilli, R, Gassull, MA, Escher, JC, Moser, G, Munkholm, P, Forbes, A, Hommes, DW, Lochs, H, Angelucci, E, Cocco, A, Vucelic, B, Hildebrand, H, Kolacek, S, Riis, L, Lukas, M, de Franchis, R, Hamilton, M, Jantschek, G, Michetti, P, O'Morain, C, Anwar, MM, Freitas, JL, Mouzas, IA, Baert, F, Mitchel, R, Hawkey, CJ
المصدر: Gut. 55(55 Suppl 1):i36-58
مصطلحات موضوعية: Medicin och hälsovetenskap
-
10دورية أكاديمية
المؤلفون: Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Sebastian S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L, Ricci C, and I-CARE Collaborator Group.
المساهمون: Peyrin-Biroulet, L, Rahier, Jf, Kirchgesner, J, Abitbol, V, Sebastian, S, Armuzzi, A, Karmiris, K, Gisbert, Jp, Bossuyt, P, Helwig, U, Burisch, J, Yanai, H, Doherty, Ga, Magro, F, Molnar, T, Löwenberg, M, Halfvarson, J, Zagorowicz, E, Rousseau, H, Baumann, C, Baert, F, Beaugerie, L, Ricci, C, and I-CARE Collaborator, Group.
الوصف: Background and aims: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE (IBD Cancer and serious infections in Europe) was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with anti-tumor necrosis factor and other biologic monotherapy as well as in combination with immunomodulators. Methods: I-CARE was designed as a European prospective longitudinal observational multicenter cohort study to include patients with a diagnosis of Crohn's disease, ulcerative colitis, or IBD unclassified established at least 3 months prior to enrollment. Results: A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6169 (60.4%) patients with Crohn's disease, 3853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving azathioprine/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one-quarter of patients (26.8%) underwent prior IBD-related surgery. Sixty-six percent of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion and 1.1% had a history of colonic, esophageal, or uterine cervix high-grade dysplasia. Conclusions: I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients.
وصف الملف: ELETTRONICO
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36152897; info:eu-repo/semantics/altIdentifier/wos/WOS:000947449000001; volume:21; firstpage:771; lastpage:788; numberofpages:18; journal:CLINICAL GASTROENTEROLOGY AND HEPATOLOGY; https://hdl.handle.net/11379/578166Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85147220109
النص الكامل